$3.79
0.26%
Nasdaq, Sep 18, 04:03 pm EDT. Closed.
ISIN
US5171251003
Symbol
LRMR

Larimar Therapeutics Inc Target price 2026 - Analyst rating & recommendation

Larimar Therapeutics Inc Classifications & Recommendation

Buy
94%
Hold
6%

Larimar Therapeutics Inc Price Target

Target Price $12.75
Price $3.79
Potential
Number of Estimates 11
11 Analysts have issued a price target Larimar Therapeutics Inc 2027 . The average Larimar Therapeutics Inc target price is $12.75. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 17 analysts: 16 Analysts recommend Larimar Therapeutics Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Larimar Therapeutics Inc stock has an average upside potential 2027 of . Most analysts recommend the Larimar Therapeutics Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Earnings Per Share $ -2.27 -1.52
71.97% 33.04%
P/E negative

13 Analysts have issued a Larimar Therapeutics Inc forecast for earnings per share. The average Larimar Therapeutics Inc EPS is

$-1.52
unlock
. This is
8.43% higher
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$-1.42 14.46%
unlock
, the lowest is
$-1.72 3.61%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $-2.27 71.97%
2026
$-1.52 33.04%
unlock
2027
$-1.17 23.03%
unlock
2028
$-0.57 51.28%
unlock
2029
$-1.74 205.26%
unlock
2030
$-1.23 29.31%
unlock
2031
$-0.83 32.52%
unlock
2032
$-0.46 44.58%
unlock
2033
$-0.23 50.00%
unlock

P/E ratio

Current -2.28 9.37%
2026
-2.49 9.06%
unlock
2027
-3.24 30.12%
unlock
2028
-6.69 106.48%
unlock

Current Larimar Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Wedbush
Locked
Locked
Locked Aug 05 2026
Baird
Locked
Locked
Locked Jun 30 2026
JP Morgan
Locked
Locked
Locked May 27 2026
Wedbush
Locked
Locked
Locked May 18 2026
Wedbush
Locked
Locked
Locked Mar 20 2026
Wedbush
Locked
Locked
Locked Mar 03 2026
Wedbush
Locked
Locked
Locked Feb 25 2026
Analyst Rating Date
Locked
Wedbush:
Locked
Locked
Aug 05 2026
Locked
Baird:
Locked
Locked
Jun 30 2026
Locked
JP Morgan:
Locked
Locked
May 27 2026
Locked
Wedbush:
Locked
Locked
May 18 2026
Locked
Wedbush:
Locked
Locked
Mar 20 2026
Locked
Wedbush:
Locked
Locked
Mar 03 2026
Locked
Wedbush:
Locked
Locked
Feb 25 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today